Clinical Trials Browser

Phase 2 × INDUSTRY × exemestane × Clear all

Neoplasms

NCT04059484 2026-02-24

AMEERA-3

Phase 2 Terminated

367 enrolled 30 charts

Breast

Breast Cancer Metastatic

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Phase 2 Active not recruiting

333 enrolled

Breast

Breast Neoplasms, Recurrence

NCT06428396 2025-12-26

LITESPARK-029

Phase 2 Recruiting

120 enrolled

Breast

Breast Neoplasms

NCT02007512 2025-09-02

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Phase 2 Completed

247 enrolled 27 charts

Breast

Breast Neoplasms

NCT06957379 2025-05-04

Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

Phase 2 Active not recruiting

78 enrolled

Breast

Breast Neoplasms

NCT03272477 2024-04-17

TP-II

Phase 2 Completed

257 enrolled

Breast

Breast Neoplasms

NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Phase 2 Completed

105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

NCT03312738 2024-01-23

BOLERO-5

Phase 2 Completed

159 enrolled 25 charts

Breast

Breast Neoplasms

NCT02258451 2023-11-24

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

Phase 2 Completed

283 enrolled 22 charts

Breast

Breast Neoplasms

NCT01698918 2023-05-03

BOLERO-4

Phase 2 Completed

202 enrolled 19 charts

Breast

Breast Neoplasms

NCT02894398 2023-03-13

INGE-B

Phase 2 Completed

388 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02049957 2023-02-08

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Phase 2 Completed

118 enrolled 30 charts

Breast

Breast Neoplasms

NCT03291886 2022-06-21

Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

Phase 2 Completed

133 enrolled

Breast

Breast Neoplasms

NCT01783444 2021-02-26

BOLERO-6

Phase 2 Completed

309 enrolled 19 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01381874 2019-04-11

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Phase 2 Completed

297 enrolled 19 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01605396 2019-03-25

MK-8669-064

Phase 2 Completed

80 enrolled 13 charts

Breast

Breast Neoplasms

NCT00728949 2018-06-06

A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

Phase 2 Completed

93 enrolled 14 charts

Breast

Breast Neoplasms

NCT00615524 2018-01-12

Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02069093 2017-02-13

Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer

Phase 2 Completed

92 enrolled 9 charts

Breast

Advanced Breast Cancer

NCT01151046 2016-05-12

Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

Phase 2 Completed

118 enrolled 13 charts

Breast

Breast Neoplasms

NCT01004081 2015-10-02

Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding

Phase 2 Completed

54 enrolled

Breast

Breast Neoplasms

NCT00767520 2013-02-28

Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer

Phase 2 Completed

155 enrolled 19 charts

Breast

Breast Neoplasms

NCT00793546 2012-11-05

Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer

Phase 2 Terminated

42 enrolled 7 charts

Breast

Breast Neoplasms

NCT01658176 2012-10-29

Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT00040014 2012-02-16

Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women

Phase 2 Terminated

100 enrolled

Breast

Breast Neoplasms

NCT00174343 2011-04-22

Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients

Phase 2 Completed

46 enrolled

Breast

Breast Neoplasms

Clinical Trials

OMAHA-015

AMEERA-3

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

LITESPARK-029

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

TP-II

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

BOLERO-5

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

BOLERO-4

INGE-B

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

BOLERO-6

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

MK-8669-064

A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer

Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer

Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding

Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer

Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer

Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer

Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women

Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients